- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800
- Procedure · Biological · Drug
- Lead sponsor
- George Poultsides
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Interventions
- Panitumumab IRDye 800
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Near-Infrared Fluorescence Imaging, Panitumumab-IRDye800, Pharmacokinetic Study, Therapeutic Conventional Surgery
- Procedure · Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Head and Neck Cancer
- Interventions
- Panitumumab-IRDye800, Lymphoseek
- Drug
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Brain Tumor
- Interventions
- Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera, PDE-NEO-II
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck
- Interventions
- Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS), SPY-PHI IR9000 fluorescence imaging system (FIS), Explorer Air camera, PDE-NEO II camera, FIS-00 fluorescence imaging system (FIS), Da Vinci Firefly Imaging System, IGP-ELVIS-v4 Macroscopic Specimen Imager, Vevo 3100 LAZR-X, Pearl Triology Imaging System, Odyssey CLx Imaging System, Leica fluorescence microscope
- Drug · Device
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Head and Neck Cancer
- Interventions
- Panitumumab-IRDye800
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Malignant Brain Neoplasm, Malignant Glioma
- Interventions
- Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800, POINPOINT-IR9000
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
- Interventions
- Panitumumab-IRDye800
- Drug
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Head and Neck Cancer
- Interventions
- Panitumumab IRDye 800, da Vinci Firefly, IMAGE1 + ICG Hopkins telescope and/or VITOM
- Drug · Device
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Stanford, California